Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ticagrelor · 1 trial · 2 indications
The change from baseline in thrombus area post-treatment with BMS-986141 versus pretreatment. Baseline is defined as the last non-missing result (including repeated and unscheduled assessments) with a collection date-time less than the datetime of study medication.
| Arm | Type | Description |
|---|---|---|
| Treatment Arm 1: Ticagrelor + BMS-986141 | EXPERIMENTAL | - |
| Treatment Arm 2: Aspirin + BMS-986141 | EXPERIMENTAL | - |
| Treatment Arm 3: Ticagrelor + Aspirin + BMS-986141 | EXPERIMENTAL | - |
| Treatment Arm 4: BMS-986141 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Ticagrelor | DRUG | Specified dose on specified days |
| BMS-986141 | DRUG | Specified dose on specified days |
| Aspirin | DRUG | Specified dose on specified days |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com Inclusion Criteria: * Male or female between 18 to 75 years of age, inclusive, and body mass index (weight kg/m2) between 18 and 35 kg/m2 (inclusive), and body weight 50 kg and 1...
Ticagrelor is a small molecule being studied for use in Coronary Artery Disease. It is being evaluated in a Phase 2 clinical trial that also includes healthy participants, to assess its effect on thrombus formation when added to aspirin or other antiplatelet therapy. The drug is investigational and not yet approved.
Ticagrelor is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical research on the drug for Coronary Artery Disease, with the most recent trial completed in the United Kingdom.
Ticagrelor is in Phase 2 clinical development. The most recent trial, NCT05093790, has been completed. The drug is investigational and has not been approved for any use, so it remains in clinical development for Coronary Artery Disease.
Ticagrelor has one completed Phase 2 trial, NCT05093790, which evaluated the drug added on to aspirin or ticagrelor or the combination on thrombus formation in a thrombosis chamber model. The trial enrolled 58 participants with stable Coronary Artery Disease and healthy participants in the United Kingdom.
Ticagrelor is a small molecule that targets the P2Y12 receptor, a key player in platelet activation and thrombus formation. By inhibiting this receptor, the drug aims to reduce blood clot formation, which is relevant in Coronary Artery Disease. This mechanism is being studied in the Phase 2 trial.